JAZZ - Jazz Pharmaceuticals: Imminent Danger With A Worrying History

• Jazz Pharmaceuticals faces increased competition after a competitor was able to manufacture a generic version of their Narcolepsy drug Xyrem.
• The market for Narcolepsy, which is Jazz Pharm’s best-performing drug market, has a stable yet extremely slow growth rate.
• The company is saddled with a large amount of debt; with its future income in legal jeopardy, its ability to pay this off could be called into question.

For further details see: